Reaction
Bacterial Disease Carrier reporting signals
As of the last recalculation, Bacterial Disease Carrier appears in 719 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 258.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ciclesonide | 104 | 258.2 | 260.2 |
| Dornase Alfa | 89 | 149.8 | 150.5 |
| Benralizumab | 38 | 58.0 | 58.1 |
| Mepolizumab | 69 | 44.4 | 44.4 |
| Vancomycin Hydrochloride | 81 | 40.0 | 40.0 |
| Vancomycin | 71 | 39.3 | 39.4 |
| Tobramycin | 29 | 36.3 | 36.4 |
| Budesonide | 67 | 36.2 | 36.2 |
| Hydroxyzine Hydrochloride | 15 | 33.7 | 33.7 |
| Hydroxyzine Hydrochloride Oral | 15 | 33.7 | 33.7 |
| Loperamide Hydrochloride And Dimethicone | 35 | 33.2 | 33.2 |
| Chlorhexidine Gluconate | 10 | 32.1 | 32.1 |
| Gentamicin | 13 | 29.3 | 29.3 |
| Azithromycin | 37 | 28.0 | 28.0 |
| Lumacaftor And Ivacaftor | 8 | 27.3 | 27.3 |
| Azithromycin Monohydrate | 37 | 27.1 | 27.1 |
| Tobramycin Solution | 10 | 24.4 | 24.4 |
| Hydroxyzine | 38 | 24.3 | 24.3 |
| Gentamicin Sulfate | 13 | 24.2 | 24.3 |
| Polatuzumab Vedotin | 8 | 24.0 | 24.0 |
| Loperamide Hydrochloride | 35 | 23.8 | 23.8 |
| Tobramycin Sulfate | 10 | 23.7 | 23.7 |
| Ivacaftor | 6 | 22.0 | 22.1 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 9 | 21.1 | 21.2 |
| Amphotericin B | 8 | 18.7 | 18.7 |
| Posaconazole Delayed-Release | 6 | 15.9 | 15.9 |
| Bendamustine Hcl | 8 | 15.1 | 15.1 |
| Omalizumab | 42 | 15.1 | 15.1 |
| Daptomycin | 4 | 12.6 | 12.6 |
| Romiplostim | 5 | 9.7 | 9.7 |
| Obinutuzumab | 5 | 8.9 | 8.9 |